STANFORD UNIVERSITY

88% of EYLEA HD patients maintained ≥12-week dosing intervals at week 156, sustaining visual and anatomic improvements. EYLEA HD showed slower fluid reaccumulation and longer duration of action compared to EYLEA. Safety data remained consistent with known profiles.

A study found over 55% of Elahere users experienced vision loss due to corneal toxicity, with 69% showing signs of toxicity. Vision improved in 65% of eyes, and corneal toxicity significantly improved in almost all cases with corticosteroids and dosage adjustments.

cfDNA screening in pregnancy is most cost-effective for high-risk but not extraordinarily high-risk patients, reducing invasive tests and healthcare costs. Wide coverage raises costs by $250 per pregnancy, while targeted coverage saves $89 per patient. Precision medicine's benefits depend on policy and patient matching, not just technology.

Drew Endy convened Hoover and Stanford experts, policymakers, and business leaders, including Condoleezza Rice, to discuss biotechnology issues with Congressional staff. The inaugural Bio-Strategies and Leadership Congressional Fellowship Program covered topics like the bioeconomy, biosecurity, and synthetic biology, emphasizing the strategic importance of biology, especially in the context of China's biotech innovation. The event also highlighted the intersection of biotechnology, democracy, and national security.

IOCB Prague launches a new lab in Boston, aiming to become an outpost for Czech science abroad, with a focus on medicinal chemistry and technology transfer. The branch, supported by private donations and IOCB revenues, plans to expand with additional research labs.

New research shows cfDNA screenings for pregnancy are most cost-effective for 'middle-risk' patients, reducing invasive tests and healthcare costs. The study highlights the need for precision in applying such technologies to manage expenses effectively.

MEDiC Life Sciences secures $5M from LG and Hanmi Pharmaceutical, accelerating cancer biomarker discovery via MCAT platform, enhancing drug efficacy and market potential. The investment aims to bolster business development and advance drug discovery efforts, positioning MEDiC as a leader in functional genomics for solid tumors.

MedGenome celebrates 10 years of pioneering genomics in India, launching a corporate video to commemorate its journey. The company has introduced over 1,300 genetic tests, sequenced over 350,000 exomes and genomes, and partnered with over 5,500 hospitals and 15,000 clinicians. MedGenome aims to broaden access to affordable genetic solutions and continues to innovate in precision medicine and wellness solutions.

A three-arm, parallel groups, randomized controlled trial (NCT05698368) was designed per SPIRIT guidelines, recruiting participants via social media, flyers, email, and word of mouth. Participants, aged 45+ with knee osteoarthritis, were randomized into mindset intervention, education intervention, or no intervention groups. The primary outcomes assessed post-intervention included Exercise and Osteoarthritis mindsets, with follow-up measures of knee pain and physical activity. Secondary outcomes included knowledge, body mindsets, and activity adequacy. Statistical analysis was conducted in R, evaluating mean change scores and differences between groups.

Stanford researchers highlight the ambiguity in clinical study reporting via tables, proposing graphs to better represent participant identities and health, amid new federal laws requiring detailed sociodemographic reporting in late-stage trials.